- Home
- GLTO vs CAPT Comparison
GLTO vs CAPT Comparison
Compare GLTO & CAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- CAPT
- Stock Information
- Founded
- GLTO 2011
- CAPT 2005
- Country
- GLTO Denmark
- CAPT South Korea
- Employees
- GLTO N/A
- CAPT N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- CAPT Blank Checks
- Sector
- GLTO Health Care
- CAPT Finance
- Exchange
- GLTO Nasdaq
- CAPT Nasdaq
- Market Cap
- GLTO 23.7M
- CAPT 27.5M
- IPO Year
- GLTO 2020
- CAPT N/A
- Fundamental
- Price
- GLTO $5.72
- CAPT $0.62
- Analyst Decision
- GLTO
- CAPT
- Analyst Count
- GLTO 0
- CAPT 0
- Target Price
- GLTO N/A
- CAPT N/A
- AVG Volume (30 Days)
- GLTO 767.1K
- CAPT 4.4M
- Earning Date
- GLTO 11-04-2025
- CAPT 01-01-0001
- Dividend Yield
- GLTO N/A
- CAPT N/A
- EPS Growth
- GLTO N/A
- CAPT N/A
- EPS
- GLTO N/A
- CAPT N/A
- Revenue
- GLTO N/A
- CAPT $17,389,944.00
- Revenue This Year
- GLTO N/A
- CAPT N/A
- Revenue Next Year
- GLTO N/A
- CAPT N/A
- P/E Ratio
- GLTO N/A
- CAPT N/A
- Revenue Growth
- GLTO N/A
- CAPT 84.70
- 52 Week Low
- GLTO $2.01
- CAPT $0.37
- 52 Week High
- GLTO $31.70
- CAPT $1.94
- Technical
- Relative Strength Index (RSI)
- GLTO 42.06
- CAPT 37.26
- Support Level
- GLTO $7.02
- CAPT $0.50
- Resistance Level
- GLTO $7.64
- CAPT $0.90
- Average True Range (ATR)
- GLTO 0.58
- CAPT 0.07
- MACD
- GLTO -0.55
- CAPT -0.01
- Stochastic Oscillator
- GLTO 0.25
- CAPT 30.00
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About CAPT Captivision Inc.
Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.